Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug takes aim at Hard-to-Treat blood cancers

NCT ID NCT05131022

Disease control Sponsor: Nurix Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goals are to find a safe dose and see if the drug can shrink tumors.

Why investors are watching

Nurix Therapeutics is testing NX-5948, a drug that degrades BTK, a protein that helps certain blood cancers grow, in people whose cancers have returned or stopped responding to treatment. This is the first human study of the drug, and for a small company, early signs of safety and tumor shrinkage in a phase 1 trial can determine whether the drug moves forward. A clear signal of activity in this 572-person study would validate the company's main research approach.

If it works: If NX-5948 shows acceptable safety and shrinks tumors in a meaningful share of patients, Nurix could advance the drug to later-stage trials and attract partnership interest. That outcome would support the company's value as a developer of targeted cancer therapies.

If it fails: Phase 1 trials often fail because the drug proves too toxic or shows little benefit, and Nurix has no other late-stage products to fall back on. A disappointing readout or a delay in enrollment could hurt the company's prospects and its ability to fund future work.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 572 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Age ≥18 years * Patients in Phase 1a (Dose Escalation) must have histologically confirmed R/R CLL, SLL, DLBCL (subgroups include Richter-transformed DLBCL, germinal center B-cell type, activated B-cell type, high-grade B-cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangements, high-grade B-cell lymphomas NOS), FL, MCL, MZL (subtypes include EMZL, MALT, NMZL, SMZL), WM, or PCNSL. * Patients in Phase 1a must meet the following: o For non-PCNSL indications, received at least 2 prior lines of therapy and have no other available therapies known to provide clinical benefit. For PCNSL, received at least 1 prior line of therapy * Patients in Phase 1b (Safety and Cohort Expansion) must have 1 of the following histologically documented B-cell malignancies, must meet criteria for systemic treatment, and must have received prior therapies and/or molecular features based on details described for each cohort: CLL or SLL, DLBCL, MCL, FL, MZL, WM, or PCNSL/SCNSL. * Measurable disease per response criteria specific to the malignancy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (0-2 for patients with PCNSL and secondary CNS involvement). * Adequate organ and bone marrow function Key Exclusion Criteria: * Known or suspected active prolymphocytic leukemia or Richter's transformation to Hodgkin's lymphoma prior to study enrollment * Prior treatment for the indication under study for anti-cancer intent that includes: 1. Radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation). 2. Prior systemic chemotherapy within 2 weeks of planned start of study drug. 3. Prior monoclonal antibody therapy within 4 weeks of planned start of study drug, except for patients enrolling in Cohort 16 (CLL with secondary wAIHA) where a 16-week washout period is required. 4. Prior small molecule therapy within 2 weeks or 5 half-lives (whichever is shorter) of planned start of study drug. 5. Autologous or allogeneic stem cell transplant within 100 days prior to planned start of study drug. 6. Chimeric antigen receptor (CAR) T-cell therapy within 100 days prior to start of study drug (within 60 days prior to start of study drug for Phase 1b). 7. Use of systemic corticosteroids outside of dosing limits described below and within 7 days prior to initiation of study treatment excepting those used as prophylaxis for radio diagnostic contrast. Patients with PCNSL/SCNSL: no greater than 40 mg/day prednisone, or equivalent. Patients with PCNSL/SCNSL using greater than 20 mg/day prednisone, or equivalent, must be clinically stable at that dose for 7 days. All other diagnoses: no greater than 20 mg/day prednisone or equivalent. 8. Use of systemic immunosuppressive drugs other than systemic corticosteroids for any medical condition within 60 days prior to first dose of study drug 9. Previously treated with a BTK degrader * Active, uncontrolled autoimmune hemolytic anemia (except for patients enrolling in Cohort 16) or active, uncontrolled autoimmune thrombocytopenia. * Patient has any of the following within 6 months of planned start of study drug: 1. Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, or placement of a coronary arterial stent 2. Uncontrolled atrial fibrillation or other clinically significant arrhythmias, conduction abnormalities, or New York Heart Association (NYHA) class III or IV heart failure 3. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), stroke, or intracranial hemorrhage 4. Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, severe congenital heart disease, or persistent uncontrolled hypertension defined as systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg despite optimal medical management) * Bleeding diathesis, or other known risk for acute blood loss. * History of Grade ≥ 2 hemorrhage within 28 days of planned start of study drug. * Active known concurrent malignancy or malignancy other than the one under study within the past 3 years. (Exceptions include, but are not limited to, patients with more recent history of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast may enroll if they have undergone curative therapy and have no evidence of disease).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia (CLL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma follicular lymphoma lymphoma Lymphoma, B-Cell, Marginal Zone mantle cell lymphoma marginal zone lymphoma primary central nervous system lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia (CLL) Diffuse large B cell lymphoma (DLBCL) Follicular lymphoma (FL) Mantle cell lymphoma (MCL) Marginal zone lymphoma (MZL) Primary central nervous system lymphoma (PCNSL) Secondary central nervous system lymphoma (SCNSL) Small lymphocytic lymphoma (SLL) Waldenstrom macroglobulinemia (WM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    53 sites in 8 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • ASST Spedali Civili Brescia

    WITHDRAWN

    Brescia, 25123, Italy

  • AidPort sp. Zo.o

    RECRUITING

    Skórzewo, Greater Poland Voivodeship, 60-185, Poland

  • CHRU de Nancy

    RECRUITING

    Vandœuvre-lès-Nancy, 54500, France

  • CHU Angers

    RECRUITING

    Angers, 49933, France

  • CHU Bordeaux

    RECRUITING

    Pessac, 33604, France

  • CHU de Nantes

    RECRUITING

    Nantes, 44093, France

  • CHU de Poitiers

    RECRUITING

    Poitiers, 86021, France

  • Cayuga Medical Center

    WITHDRAWN

    Ithaca, New York, 14850, United States

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • Clatterbridge Cancer Center NHS Foundation Trust

    RECRUITING

    Liverpool, L7 8YA, United Kingdom

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Colorado Blood Cancer Institute

    RECRUITING

    Denver, Colorado, 80218, United States

  • Duke University Medical Center

    RECRUITING

    Durham, North Carolina, 27705, United States

  • Erasmus MC

    RECRUITING

    Rotterdam, 3015 GD, Netherlands

  • Florida Cancer Specialists

    RECRUITING

    Sarasota, Florida, 34232, United States

  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    RECRUITING

    Rome, 00168, Italy

  • Hospital Clínic de Barcelona

    RECRUITING

    Barcelona, 08036, Spain

  • Hospital Fundación Jimenez Díaz - START Madrid

    RECRUITING

    Madrid, 28040, Spain

  • Hospital Ramón y Cajal

    RECRUITING

    Madrid, 28034, Spain

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario de Cabuenes

    RECRUITING

    Gijón, 33203, Spain

  • Huntsman Cancer Institute

    WITHDRAWN

    Salt Lake City, Utah, 84112, United States

  • Hôpital Avicenne

    RECRUITING

    Bobigny, 93009, France

  • Hôpitaux Universitaires de Genève

    WITHDRAWN

    Geneva, 1205, Switzerland

  • IRCCS - AOU di Bologna

    WITHDRAWN

    Bologna, 40138, Italy

  • IRCCS Ospedale San Raffaele

    RECRUITING

    Milan, 20132, Italy

  • IRCCS Ospedale San Raffaele - Università Vita-Salute San Raffaele di Milano

    RECRUITING

    Milan, 20132, Italy

  • Inselspital - Universitatsklinik Bern

    WITHDRAWN

    Bern, 3010, Switzerland

  • Institut Curie-Site Saint-Cloud

    RECRUITING

    Saint-Cloud, 92210, France

  • Istituto Oncologico della Svizzera Italiana

    RECRUITING

    Bellinzona, Switzerland

  • Kantonsspital St.Gallen

    WITHDRAWN

    Sankt Gallen, 9007, Switzerland

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Medical University of Lublin

    RECRUITING

    Lublin, 20-090, Poland

  • Memorial Sloan Kettering Cancer Center

    ACTIVE_NOT_RECRUITING

    New York, New York, 10065, United States

  • National Institute of Health

    RECRUITING

    Bethesda, Maryland, 20814, United States

  • National Institute of Oncology Warszawa

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Oxford University Hospitals NHS Foundation Trust

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

  • Pratia MCM

    RECRUITING

    Krakow, Lesser Poland Voivodeship, 30-272, Poland

  • Pratia MTZ

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-172, Poland

  • Pratia Onkologia Katowice

    RECRUITING

    Katowice, Silesian Voivodeship, 40-519, Poland

  • Radboud University Medical Center

    RECRUITING

    Nijmegen, 6525 GA, Netherlands

  • Royal Marsden NHS Foundation Trust

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

  • Sarah Cannon Research Institute UK

    RECRUITING

    London, W1G 6AD, United Kingdom

  • St. Bartholomew's Hospital, Barts NHS Trust

    RECRUITING

    London, EC1A 7BE, United Kingdom

  • St. James Hospital

    RECRUITING

    Leeds, LS9 7TF, United Kingdom

  • The Beatson WOS Cancer Center

    RECRUITING

    Glasgow, Scotland, G12 0YN, United Kingdom

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, Manchester, M20 4BX, United Kingdom

  • University Clinical Hostpital in Wroclaw

    RECRUITING

    Wroclaw, Lower Silesian Voivodeship, 50-367, Poland

  • University Hospital Southampton NHS Foundation Trust

    RECRUITING

    Southampton, SO16 6YD, United Kingdom

  • University Hospital Zurich

    RECRUITING

    Zurich, 8091, Switzerland

  • University Hospitals Plymouth NHS Trust

    RECRUITING

    Plymouth, PL6 8DH, United Kingdom

  • University Medical Center Groningen

    WITHDRAWN

    Groningen, 9713 GZ, Netherlands

  • University Medical Center Utrecht

    RECRUITING

    Utrecht, 3584 CX, Netherlands

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

  • University of Cincinnati Medical Center

    RECRUITING

    Cincinnati, Ohio, 45219, United States

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Pennsylvania, Abramson Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Universitätsspital Basel

    RECRUITING

    Basel, 4031, Switzerland

  • Winship Cancer Institute of Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Yale Cancer Center

    RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.